Breast Stereotactic Core Biopsy/Fine Needle Aspiration

  • Author: Hemant Singhal, MD, MBBS, FRCS(Edin), FRCSC; Chief Editor: Meda Raghavendra (Raghu), MD  more...
Updated: Dec 28, 2015


The establishment of national breast-screening programs in Europe and North America has led to an increase in the detection of small or impalpable breast lesions. The ability to achieve an accurate histopathologic diagnosis of these lesions is crucial to any screening program in terms of appropriate treatment planning and patient counseling.

Stereotactic breast needle biopsy refers to the sampling of nonpalpable or indistinct breast lesions by using techniques that enable the spatial localization of the lesion within the breast. The word stereotactic is derived from Greek and Latin roots meaning "touching in space." Stereotactic techniques have evolved in parallel with the trend in breast conservation and minimally invasive surgery.

In the past, impalpable breast lesions would have been surgically excised after needle localization, resulting in a vast number of surgeries for nonmalignant mammographic abnormalities. In the United States, it is estimated that more than a million surgical breast biopsies are performed, and in only 15-30% are the samples subsequently found to be malignant.

Role of stereotactic needle biopsy

Compared with open surgical biopsy, needle biopsy causes less trauma and disfigurement and is performed as an outpatient procedure with the patient under local anesthetic.[1] Stereotactic needle biopsy is an important tool in the diagnosis of breast lesions as part of the triple assessment, which includes clinical, radiologic, and cytohistopathologic studies.[2]

Definitively diagnosing these lesions with needle biopsy has several advantages. For benign lesions, establishing a definitive diagnosis obviates unnecessary surgical excision or protracted follow-up, both of which are costly in psychosocial and resource terms.[1, 3, 4, 5, 6] A definitive diagnosis of cancer allows the patient to make an informed choice and to obtain counseling before surgery. It also facilitates in the planning of multimodal treatment in terms of neoadjuvant chemotherapy, the type of procedure, and early or delayed reconstruction.

The importance of achieving preoperative diagnosis is further emphasized in the quality objectives of the United Kingdom's national breast-screening program to minimize unnecessary benign surgical biopsy and to ensure that more than 70% of women with cancer have a preoperative diagnosis.[7]

Techniques and principles of stereotaxis

Because most of the lesions detected during screening are impalpable, subsequent needle biopsy must be image-guided. Ultrasonography-guided biopsy is usually the most straightforward approach, but lesions better seen on mammography images, particularly microcalcifications, require stereotactic localization.

The principles of localization involve mapping the distance between the geometric center of the breast with the target lesion in 2 different planes and then projecting the coordinates onto the patient's breast (see image below).

Stereotactic images obtained during a prone-table Stereotactic images obtained during a prone-table biopsy procedure.

Earlier techniques in stereotaxis used mammographic projections to localize the target lesion within the breast. Advances in digital mammography have since superseded manual computations. Dedicated stereotactic equipment that performs localization with fixation of the breast is now in use (see image above).[10, 11, 12, 13] Stereotactic techniques have also been developed within other imaging modalities, including ultrasonography and magnetic resonance imaging (MRI). These techniques offer more options and greater flexibility in performing stereotactic biopsy.

Digital tomosynthesis creates a 3-dimensional picture of the breast using x-rays. It has been approved by the US Food and Drug Administration (FDA), but it is not yet considered the standard of care for breast care screening and is only available in limited hospitals. It takes multiple x-ray pictures of each breast from many angles. The breast is positioned in the same way as conventional mammography but with limited pressure. The x-ray tube moves in an arc around the breast while numerous images are taken within a few seconds. The information is then relayed to a computer, which generates highly focussed 3-dimensional images throughout the breast.

Hologic Inc recently launched the world's first 3-dimensional breast biopsy option "Affirm 3D". The procedure can be of benefit in targeting lesions that cannot be easily detected in 2-dimensional images or when using other modalities. It is claimed to also target lesions faster and reduce patient procedure time.

Relevant Anatomy

The breast is made up of fatty tissue and glandular, milk-producing tissues. The ratio of fatty tissue to glandular tissue varies among individuals. In addition, with the onset of menopause (ie, decrease in estrogen levels), the relative amount of fatty tissue increases as the glandular tissue diminishes.

The base of the breast overlies the pectoralis major muscle between the second and sixth ribs in the nonptotic state. The gland is anchored to the pectoralis major fascia by the suspensory ligaments first described by Astley Cooper in 1840. These ligaments run throughout the breast tissue parenchyma from the deep fascia beneath the breast and attach to the dermis of the skin. Since they are not taut, they allow for the natural motion of the breast.

For more information about the relevant anatomy, see Breast Anatomy.



See the list below:

  • The main application of stereotactic needle biopsy is in sampling nonpalpable breast lesions. It also has an important role in the biopsy of small, indistinct lesions, particularly those occurring in association with surgical scarring, fibrosis, or prosthetic implants. [8, 9]
  • A further indication is for repeat biopsy in cases in which previous biopsy results are inconclusive. This situation often occurs when the tumor has both benign and malignant or preinvasive components.


See the list below:

  • Local anaesthesia is mainly used for stereotactic biopsy.


See the list below:

  • Although core biopsy has improved the accuracy of image-guided needle biopsy in the diagnosis of impalpable lesions, the problems with underestimation and the potential for sampling error has led to more invasive and larger-volume percutaneous biopsy devices. The 2 main types are (1) vacuum-assisted biopsy devices, such as the Mammotome device (Ethicon Endo-Surgery, Inc, Cincinnati, Ohio) and the Minimally Invasive Breast Biopsy (MIBB) device (US Surgical, Norwalk, Conn), and (2) image-guided single-cylinder excision alternatives, such as the Advanced Breast-Biopsy Instrumentation (ABBI; US Surgical). The common denominator of these devices is their ability to sample larger tissue volumes.
  • The Mammotome probe, for example, consists of an outer shell with an aperture at its end for collecting tissue. It is a single-insertion device that uses vacuum suction to pull the target tissue into the collecting aperture. The tissue is then excised by a rotating cutter. Multiple harvests can be performed 360º around the lesion while the probe remains in the lesion during the whole procedure.
  • Although both 14- and 11-gauge needles, or probes, were initially available, only the 11-gauge probe is now widely used. The device can be used under sonographic guidance or stereotactic guidance; the patient is prone or upright with the use of certain units, with adequate room to accommodate the device.
  • The vacuum device has been demonstrated to be superior in the diagnosis of DCIS compared with a 14-gauge core biopsy, with 6% of vacuum-biopsy DCIS found to be invasive carcinoma at surgery compared with 21% with 14-gauge core biopsy. [24, 28] Repeat biopsy rates for inadequate sampling of microcalcifications is also significantly lower when using vacuum biopsy (11.6%) compared with core biopsy (23.7%), although an equal proportion of malignancy is diagnosed following rebiopsy. [29] Although vacuum biopsy appears to be nearly 3 times more accurate than core biopsy in the diagnosis of ADH, underestimation still occurs in 18-25% of cases. [23, 25]
  • Because vacuum biopsy removes more tissue during sampling than core biopsy, complete removal of the mammographic abnormality has been reported [28, 30] ; however, this is not always correlated with removal of the pathologic lesion at surgery. [24] A localizing clip can be inserted if the mammographic lesion is small; this clip can potentially be removed during vacuum biopsy. Thus far, no cases or tumor track seeding has been described, although benign epithelial displacement has been described. [31] The likelihood of this occurrence is probably minimized if the operator chooses to insert the probe into position rather than fire it into place.
  • The ABBI system similarly uses a vacuum-assisted coupling to harvest breast tissue. This system was developed with both diagnostic and therapeutic applications. The ABBI device is more invasive, with a diameter of 5-20 mm, and it is restricted to prone-table systems only. It utilizes the insertion of a localizing T-wire. A single, whole cylinder of tissue is removed after transection with an electrocautery snare.
  • Because the volume of tissue removed is larger and complete, this method offers the theoretical advantages of an increase in diagnostic accuracy due to sample size and the potential to assess the excision margins of an incidentally removed malignant tumor to determine its complete removal. However, the failure rate of ABBI procedures appears to be high. Rates of up to 31.5% have been reported. [12, 32, 33, 34, 35, 36] These failures appear to be due to a whole host of reasons, including poor patient selection, technical problems with the T-bar, and failure to remove the tissue.


Fine needle aspiration biopsy

See the list below:

  • Fine-needle aspiration (FNA) is no longer the criterion standard for initial evaluation of all palpable breast masses. However, it is particularly useful in the evaluation of cystic lesions detected by ultrasonography.
  • FNA results are reported as benign, suggestive of malignancy, or nondiagnostic. Aspiration of a benign cystic lesion should result in collapse of the cavity. Documentation of complete collapse by follow-up ultrasonography may be helpful in decreasing the incidence of recurrence. Persistence of a palpable mass and recurrence following aspiration are general indications for further workup.
  • The use of FNA does confer a couple of advantages: it is inexpensive and quick to perform. The results can be made available rapidly, enabling a 1-stop diagnostic and results clinic. Excellent results with FNA and triple assessment are reported in the literature. This approach has an accuracy of over 90% for palpable breast lesions when all 3 components are concordant for benign or malignant disease. However, in as many as 40% of cases, the findings are not concordant. [2]
  • Moreover, FNA is an operator-dependent technique, and the reporting of breast cytologic results is more demanding than histologic analysis. The degree of expertise required is not always available. Findings from cellular samples are limited in that the reviewer may not be able to determine the grade or invasiveness of the tumor. It is also difficult to diagnose lobular carcinoma on the basis of cytologic results [8] ; however, there is evidence to indicate that ultrasound and FNA biopsy are similarly useful for the axillary staging of patients with invasive lobular and invasive ductal carcinoma. [14]
  • The technique of FNA is determined largely by individual surgeon preference, which may, in part, reflect hand size and strength. A 21-gauge (green) needle is used most commonly, although in expert hands, a 23-gauge (blue) needle can yield as much information, with less discomfort and bruising. Some clinicians opt for a hand-held 10-mL syringe, whereas others prefer a 20-mL syringe used with a syringe holder. Syringe holders allow a vacuum to be maintained easily but can make control of the needle tip less precise.
  • To perform FNA, the skin should be disinfected with an alcohol wipe, and the needle is passed through the lesion a number of times, while maintaining suction and steadying the breast tissue with the other hand. Appreciating the potential risk of pneumothorax is important when performing needle biopsies of the breast, and wherever possible, the needle should be angled tangentially to the chest wall. Continue sampling until aspirate is observed at the bottom of the plastic portion of the needle.
  • Transfer the aspirate to slides. Spread the aspirate thin enough to visualize individual cells. The slides may be air-dried or fixed according to the preference of the local laboratory. Cytospin preparations of the aspirate may allow a greater number of slides to be made.
  • A cytologist then examines the slide. The success of FNA biopsy is highly dependent on the expertise of the cytologist, as well as on accurate localization.

Core-needle biopsy

See the list below:

  • In view of the limitations with FNA, core-needle biopsy was developed. The core needles are of a larger caliber than the fine needles and are mounted onto a spring-loaded device that allows small cylinders of tissue to be cut and collected within the notch of the needle. Technically, the best core-biopsy samples are obtained by using 14-gauge needles. The optimal number of passes required vary according to the mammographic appearances of the lesions being sampled, with fewer passes required for solid lesions compared with microcalcifications. Several investigators have shown that a minimum of 5-6 passes is required when sampling microcalcifications to minimize sampling error. [15, 16, 17] Specimen radiography is also required to ensure that representative calcifications are obtained (see image below).
    Comparison of the size of specimens obtained durin Comparison of the size of specimens obtained during core biopsy with a 14-gauge needle (left) and those obtained during vacuum biopsy with a 16-gauge needle (right).
  • A few false-positive results are reported, and these are attributed to the removal of the lesion by means of core biopsy or a surgical failure to remove the lesion. The reported false-negative rate for malignancy with core biopsy is in the range of 2-6.7%, with a mean rate of 4.4%. [18, 19] These false-negative results are more likely to occur with microcalcifications. In the United Kingdom's NHS Breast Screening Programme, the actual false-negative rate is more variable. [7, 20] This variation may represent the wide range of experience and expertise in the technique, as some units may still be moving from FNA to core biopsy.
  • Although the vast majority of the published literature on stereotactic core biopsy involves the use of dedicated, prone-table biopsy units, better results have been reported in United Kingdom centers that switch from FNA to core biopsy by using upright stereotactic devices. [21, 22] With the advent of digital acquisition with upright stereotactic units, the accuracy could reasonably be expected to improve, and this improvement has certainly been the experience with early adopters of such systems (Evans AJ, personal communications, 2003).
  • The main advantage of core-needle biopsy is that it enables histologic diagnosis, which is vital to the planning of subsequent surgery and treatment of the patient. Stereotactic core-needle biopsy using a 14-gauge needle is widely accepted to be sensitive (90.5%) and specific (98.3%) in diagnosing breast masses, compared with 62.4% and 86.9%, respectively, for FNA. Core-needle biopsy can also be used to detect in situ as well as invasive malignancy. In addition, the status of estrogen receptors in the samples can easily be ascertained.
  • Certain histologic results should be interpreted with caution. With core biopsy, a propensity to underestimate certain pathology exists. Over 50% of all cases of atypical ductal hyperplasia (ADH) diagnosed with core biopsy prove malignant at surgery, and invasive carcinoma is found in up to 33% of core biopsy-confirmed ductal carcinoma in situ (DCIS). [23, 24, 25]
  • Radial scars diagnosed by means of core biopsy should also be regarded as high-risk lesions requiring excision. [19] It is also more difficult to achieve a diagnosis using core biopsy in low-risk calcifications or where the underlying cause is subsequently proven to be benign. [26] Therefore, core biopsy results should always be carefully analyzed to ensure that radiologic and pathologic concordance exists. One case report also raised concerns of malignant seeding of the needle track after core biopsy of a mucinous carcinoma [27] ; however, the significance and true incidence of this phenomenon remains uncertain

Wide-bore needle biopsy

See the list below:

  • A Tru-Cut needle, ideally 14-gauge, is used for core biopsy. Because of the fibrous nature of much breast tissue, adequate samples are best obtained using a spring-loaded firing device, such as the Biopty-Cut (Bard Biopsy Systems, Tempe, Ariz) system. The procedure is often less painful than FNA despite the wider-bore needle.
  • After subcutaneous injection of local anesthetic, cores of tissue can be taken and should be fixed immediately in formalin. If the lesion contains calcification based on the mammogram findings, radiographs of the cores are taken to confirm the presence of calcification and that the cores are representative. The risk of bruising with wide-bore needle biopsies is higher than with FNA. For this reason, anticoagulants should be stopped, when possible, before biopsy and a pressure dressing is applied, usually for at least 24 hours.
  • Often, the samples are large enough to allow detailed histologic assessment, including tumor type and grade and hormone receptor status, but sampling error may occur if the cores are not representative of the entire lesion.

Vacuum-assisted core biopsy

See the list below:

  • With vacuum-assisted core biopsy devices (Mammotome, Ethicon Endo-Surgery, Cincinnati, Ohio; Minimally Invasive Breast Biopsy [MIBB], United States Surgical, Norwalk, Conn), an 11-gauge needle is positioned using ultrasonographic or mammographic guidance, and targeted breast tissue is drawn, cut, and saved in a collecting chamber. The procedure is performed under local anesthesia. These devices are relatively expensive, but they may be an alternative to open surgery for the therapeutic excision of benign lesions less than 15 mm or for additional tissue biopsy in patients with microcalcification or borderline breast lesions.


See the list below:

  • Complication rates of Advanced Breast-Biopsy Instrumentation (ABBI) procedures requiring medical or surgical intervention are significantly higher than those of core biopsy and vacuum biopsy, with rates of approximately 1.1% for ABBI and less than 0.2% for core biopsy or vacuum biopsy. Although the complete removal of a small malignant lesion does occur, positive margin rates of 19-100% have been described. [12, 33, 35, 36, 37, 38, 39, 40] The cost has also been a subject of contention, as ABBI procedures are more expensive than any of the other percutaneous needle-biopsy techniques.

Cost-Effectiveness of Biopsy

See the list below:

  • Comparable health economic data on the comparative efficacy of image guidance modalities or needle-biopsy options may not be readily available. The costs of the consumables are not insubstantial compared with those of FNA.
  • Undoubtedly, percutaneous needle-biopsy techniques are advantageous in increasing the preoperative diagnostic accuracy of impalpable breast lesions and even in reducing the overall costs of diagnosis compared with surgical excision. [4, 5, 6, 12, 41, 42] Even so, each new and incremental development has increased the cost of the procedure. It is therefore prudent to use a biopsy technique with full knowledge and awareness of the individual strengths and weaknesses of not only the individual modality, but also the expertise available in one's institution. According to available expertise, masses may be successfully sampled with FNA or core biopsy under sonographic guidance, whereas stereotactic vacuum biopsy of small clusters of indeterminate microcalcifications may be more appropriate as a modality of choice compared with FNA or core biopsy.
  • Clearly, an evidence-based approach to the image-guided modality and appropriate sampling modality for particular lesion types, combined with health economic measures is required. Due considerations must also be given to patient acceptance and outcome measures. A United Kingdom multicenter study evaluating the health economics and cost-effectiveness of 14-gauge core biopsies and biopsies using the Mammotome with conventional or digital upright stereotactic units and a prone table is underway.
  • The pathologic results should always be carefully evaluated in accordance to the level of clinical and radiologic suspicion in a multidisciplinary setting to ensure that the appropriate management decision is reached. Used in this manner, image-guided percutaneous needle biopsy can be used effectively to ensure that most palpable and impalpable breast lesions are diagnosed with accuracy and certainty.
  • The technique is safe and performed with the patient under local anesthesia. The complication rate is low, this method reduces intangible costs due to physical and psychologic morbidity.
Contributor Information and Disclosures

Hemant Singhal, MD, MBBS, FRCS(Edin), FRCSC Consultant Surgeon, Clementine Churchill Hospital; Director of Breast Service, Medanta The Medicity; Senior Lecturer, Department of Surgery, Imperial College School of Medicine

Hemant Singhal, MD, MBBS, FRCS(Edin), FRCSC is a member of the following medical societies: Royal College of Physicians and Surgeons of Canada, Royal College of Surgeons of Edinburgh

Disclosure: Nothing to disclose.


William Teh, MBChB, FRCR Lead Cancer Clinician, Department of Radiology, Northwick Park Hospital; Director of Screening, North London Breast Screening Service, UK

William Teh, MBChB, FRCR is a member of the following medical societies: British Institute of Radiology, British Medical Association, Royal College of Radiologists

Disclosure: Received honoraria from Hologic for speaking and teaching.

Avi Agrawal, MBBS, MSc FRCS(Ed), FRCS(Gen Surg), Consultant Oncoplastic Breast Surgeon, Portsmouth Hospitals, NHS Trust, UK

Disclosure: Nothing to disclose.

Specialty Editor Board

Bernard D Coombs, MB, ChB, PhD Consulting Staff, Department of Specialist Rehabilitation Services, Hutt Valley District Health Board, New Zealand

Disclosure: Nothing to disclose.

Edward Azavedo, MD, PhD Director of Clinical Breast Imaging Services, Associate Professor, Department of Radiology, Karolinska University Hospital, Sweden

Edward Azavedo, MD, PhD is a member of the following medical societies: Radiological Society of North America, Swedish Medical Association, Swedish Society of Medicine

Disclosure: Nothing to disclose.

Chief Editor

Meda Raghavendra (Raghu), MD Associate Professor, Interventional Pain Management, Department of Anesthesiology, Chicago Stritch School of Medicine, Loyola University Medical Center

Meda Raghavendra (Raghu), MD is a member of the following medical societies: American Society of Anesthesiologists, American Society of Regional Anesthesia and Pain Medicine, American Association of Physicians of Indian Origin

Disclosure: Nothing to disclose.

Additional Contributors

John M Lewin, MD Section Chief, Breast Imaging, Diversified Radiology of Colorado, PC; Associate Clinical Professor, Department of Preventative Medicine and Biometrics, University of Colorado School of Medicine

John M Lewin, MD is a member of the following medical societies: American College of Radiology, American Roentgen Ray Society, Radiological Society of North America, Society of Breast Imaging

Disclosure: Received consulting fee from Hologic, Inc. for consulting; Received grant/research funds from Hologic, Inc. for research.

  1. Pettine S, Place R, Babu S, Williard W, Kim D, Carter P. Stereotactic breast biopsy is accurate, minimally invasive, and cost effective. Am J Surg. 1996 May. 171(5):474-6. [Medline].

  2. Salami N, Hirschowitz SL, Nieberg RK, Apple SK. Triple test approach to inadequate fine needle aspiration biopsies of palpable breast lesions. Acta Cytol. 1999 May-Jun. 43(3):339-43. [Medline].

  3. Hatmaker AR, Donahue RM, Tarpley JL, Pearson AS. Cost-effective use of breast biopsy techniques in a Veterans health care system. Am J Surg. 2006 Nov. 192(5):e37-41. [Medline].

  4. Burkhardt JH, Sunshine JH. Core-needle and surgical breast biopsy: comparison of three methods of assessing cost. Radiology. 1999 Jul. 212(1):181-8. [Medline]. [Full Text].

  5. Lind DS, Minter R, Steinbach B, et al. Stereotactic core biopsy reduces the reexcision rate and the cost of mammographically detected cancer. J Surg Res. 1998 Jul 15. 78(1):23-6. [Medline].

  6. Lee CH, Egglin TK, Philpotts L, Mainiero MB, Tocino I. Cost-effectiveness of stereotactic core needle biopsy: analysis by means of mammographic findings. Radiology. 1997 Mar. 202(3):849-54. [Medline]. [Full Text].

  7. NHS Breast Screening Radiologists Quality Assurance Committee. Quality Assurance Guidelines for Mammography: Including Radiographic Quality Control. Sheffield, UK: NHS Cancer Screening Programmes. April 2006. [Full Text].

  8. Sadler GP, McGee S, Dallimore NS, et al. Role of fine-needle aspiration cytology and needle-core biopsy in the diagnosis of lobular carcinoma of the breast. Br J Surg. 1994 Sep. 81(9):1315-7. [Medline].

  9. Jackman RJ, Lamm RL. Stereotactic histologic biopsy in breasts with implants. Radiology. 2002 Jan. 222(1):157-64. [Medline]. [Full Text].

  10. Duijm LE, Groenewoud JH, Roumen RM, de Koning HJ, Plaisier ML, Fracheboud J. A decade of breast cancer screening in The Netherlands: trends in the preoperative diagnosis of breast cancer. Breast Cancer Res Treat. 2007 Nov. 106(1):113-9. [Medline].

  11. Tate PS, Rogers EL, McGee EM, et al. Stereotactic breast biopsy: a six-year surgical experience. J Ky Med Assoc. 2001 Mar. 99(3):98-103. [Medline].

  12. Velanovich V, Lewis FR Jr, Nathanson SD, Strand VF, Talpos GB, Bhandarkar S, et al. Comparison of mammographically guided breast biopsy techniques. Ann Surg. 1999 May. 229(5):625-30; discussion 630-3. [Medline]. [Full Text].

  13. Becker W. Stereotactic localization of breast lesions. Radiology. 1979 Oct. 133(1):238-40. [Medline].

  14. Boughey JC, Middleton LP, Harker L, et al. Utility of ultrasound and fine-needle aspiration biopsy of the axilla in the assessment of invasive lobular carcinoma of the breast. Am J Surg. 2007 Oct. 194(4):450-5. [Medline].

  15. Rich PM, Michell MJ, Humphreys S, Howes GP, Nunnerley HB. Stereotactic 14G core biopsy of non-palpable breast cancer: what is the relationship between the number of core samples taken and the sensitivity for detection of malignancy?. Clin Radiol. 1999 Jun. 54(6):384-9. [Medline].

  16. Brenner RJ, Fajardo L, Fisher PR, et al. Percutaneous core biopsy of the breast: effect of operator experience and number of samples on diagnostic accuracy. AJR Am J Roentgenol. 1996 Feb. 166(2):341-6. [Medline]. [Full Text].

  17. Liberman L, Dershaw DD, Rosen PP, Abramson AF, Deutch BM, Hann LE. Stereotaxic 14-gauge breast biopsy: how many core biopsy specimens are needed?. Radiology. 1994 Sep. 192(3):793-5. [Medline]. [Full Text].

  18. Lee CH, Philpotts LE, Horvath LJ, Tocino I. Follow-up of breast lesions diagnosed as benign with stereotactic core-needle biopsy: frequency of mammographic change and false-negative rate. Radiology. 1999 Jul. 212(1):189-94. [Medline]. [Full Text].

  19. Jackman RJ, Nowels KW, Rodriguez-et al. Stereotactic, automated, large-core needle biopsy of nonpalpable breast lesions: false-negative and histologic underestimation rates after long-term follow-up. Radiology. 1999 Mar. 210(3):799-805. [Medline]. [Full Text].

  20. Britton PD. Fine needle aspiration or core biopsy. Breast. 1999. 8(1):1-4.

  21. Britton PD, Flower CD, Freeman AH, et al. Changing to core biopsy in an NHS breast screening unit. Clin Radiol. 1997 Oct. 52(10):764-7. [Medline].

  22. Litherland JC, Evans AJ, Wilson AR, et al. The impact of core-biopsy on pre-operative diagnosis rate of screen detected breast cancers. Clin Radiol. 1996 Aug. 51(8):562-5. [Medline].

  23. Brem RF, Behrndt VS, Sanow L, Gatewood OM. Atypical ductal hyperplasia: histologic underestimation of carcinoma in tissue harvested from impalpable breast lesions using 11-gauge stereotactically guided directional vacuum-assisted biopsy. AJR Am J Roentgenol. 1999 May. 172(5):1405-7. [Medline]. [Full Text].

  24. Jackman RJ, Burbank FH, Parker SH, et al. Accuracy of sampling ductal carcinoma in situ by three stereotactic breast biopsy methods. Radiology. 1998. 209P:197-8.

  25. Jackman RJ, Burbank F, Parker SH, et al. Atypical ductal hyperplasia diagnosed at stereotactic breast biopsy: improved reliability with 14-gauge, directional, vacuum-assisted biopsy. Radiology. 1997 Aug. 204(2):485-8. [Medline]. [Full Text].

  26. Denton ERE, Michell MJ. Prone stereotactic core biopsy: results by mammographic sign in 640 cases. Presented at: Proceedings of the Annual Scientific Meeting of the Royal College of Radiologists Breast Group. 1998; Manchester, UK.

  27. Harter LP, Curtis JS, Ponto G, Craig PH. Malignant seeding of the needle track during stereotaxic core needle breast biopsy. Radiology. 1992 Dec. 185(3):713-4. [Medline]. [Full Text].

  28. Jackman RJ, Marzoni FA Jr, Nowels KW. Percutaneous removal of benign mammographic lesions: comparison of automated large-core and directional vacuum-assisted stereotactic biopsy techniques. AJR Am J Roentgenol. 1998 Nov. 171(5):1325-30. [Medline]. [Full Text].

  29. Philpotts LE, Shaheen NA, Carter D, Lange RC, Lee CH. Comparison of rebiopsy rates after stereotactic core needle biopsy of the breast with 11-gauge vacuum suction probe versus 14-gauge needle and automatic gun. AJR Am J Roentgenol. 1999 Mar. 172(3):683-7. [Medline]. [Full Text].

  30. Liberman L, Dershaw DD, Rosen PP, Morris EA, Abramson AF, Borgen PI. Percutaneous removal of malignant mammographic lesions at stereotactic vacuum-assisted biopsy. Radiology. 1998 Mar. 206(3):711-5. [Medline]. [Full Text].

  31. Liberman L, Vuolo M, Dershaw DD, et al. Epithelial displacement after stereotactic 11-gauge directional vacuum-assisted breast biopsy. AJR Am J Roentgenol. 1999 Mar. 172(3):677-81. [Medline]. [Full Text].

  32. Liberman L. Advanced Breast Biopsy Instrumentation (ABBI): analysis of published experience. AJR Am J Roentgenol. 1999 May. 172(5):1413-6. [Medline]. [Full Text].

  33. Ferzli GS, Puza T, Vanvorst-Bilotti S, Waters R. Breast Biopsies with ABBI(R): Experience with 183 Attempted Biopsies. Breast J. 1999 Jan. 5(1):26-28. [Medline].

  34. LaRaja RD, Saber AA, Sickles A. Early experience in the use of the Advanced Breast Biopsy Instrumentation: a report of one hundred twenty-seven patients. Surgery. 1999 Apr. 125(4):380-4. [Medline].

  35. Rebner M, Chesbrough R, Gregory N. Initial experience with the advanced breast biopsy instrumentation device. AJR Am J Roentgenol. 1999 Jul. 173(1):221-6. [Medline]. [Full Text].

  36. Damascelli B, Frigerio LF, Lanocita R, et al. Stereotactic excisional breast biopsy performed by interventional radiologists using the advanced breast biopsy instrumentation system. Br J Radiol. 1998 Oct. 71(850):1003-11. [Medline]. [Full Text].

  37. D'Angelo PC, Galliano DE, Rosemurgy AS. Stereotactic excisional breast biopsies utilizing the advanced breast biopsy instrumentation system. Am J Surg. 1997 Sep. 174(3):297-302. [Medline].

  38. Kelley WE, Bailey R, Bertelson C, et al. Stereotactic automated surgical biopsy using the ABBI biopsy device: a multicenter study. Breast J. 1998. 4(5):302-6.

  39. Leibman AJ, Frager D, Choi P. Experience with breast biopsies using the Advanced Breast Biopsy Instrumentation system. AJR Am J Roentgenol. 1999 May. 172(5):1409-12. [Medline]. [Full Text].

  40. Matthews BD, Williams GB. Initial experience with the advanced breast biopsy instrumentation system. Am J Surg. 1999 Feb. 177(2):97-101. [Medline].

  41. Smith DN, Christian R, Meyer JE. Large-core needle biopsy of nonpalpable breast cancers. The impact on subsequent surgical excisions. Arch Surg. 1997 Mar. 132(3):256-9; discussion 260. [Medline].

  42. Gentry CL, Henry CA. Stereotactic Percutaneous Breast Biopsy: A Comparative Analysis Between Surgeon and Radiologist. Breast J. 1999 Mar. 5(2):101-104. [Medline].

  43. Ciatto S, Houssami N, Ambrogetti D, et al. Accuracy and underestimation of malignancy of breast core needle biopsy: the Florence experience of over 4000 consecutive biopsies. Breast Cancer Res Treat. 2007 Mar. 101(3):291-7. [Medline].

  44. Pisano ED, Fajardo LL, Tsimikas J, et al. Rate of insufficient samples for fine-needle aspiration for nonpalpable breast lesions in a multicenter clinical trial: The Radiologic Diagnostic Oncology Group 5 Study. The RDOG5 investigators. Cancer. 1998 Feb 15. 82(4):679-88. [Medline]. [Full Text].

  45. Ha D, Dialani V, Mehta TS, Keefe W, Iuanow E, Slanetz PJ. Mucocele-like lesions in the breast diagnosed with percutaneous biopsy: is surgical excision necessary?. AJR Am J Roentgenol. 2015 Jan. 204(1):204-10. [Medline].

  46. Park HL, Hong J. Vacuum-assisted breast biopsy for breast cancer. Gland Surg. 2014 May. 3(2):120-7. [Medline].

Stereotactic images obtained during a prone-table biopsy procedure.
Comparison of the size of specimens obtained during core biopsy with a 14-gauge needle (left) and those obtained during vacuum biopsy with a 16-gauge needle (right).
Medscape Consult
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.